Clinical Trial Update: Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating short-course blinatumomab for eradication of measurable residual disease in B-cell acute lymphoblastic leukemia; trial current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD) | Phase 2 | Status: RECRUITING